Myesha Lacy

Myesha joined Arcellx, Inc., a clinical-stage cell therapy company in June 2021, bringing more than 25 years of experience as a communications professional providing strategy, development, and execution of internal and external communications programs for publicly traded pharmaceutical and biotechnology companies. Most recently, Myesha was Vice President, Investor Relations and Corporate Communications at Adverum Biotechnologies, an ocular gene therapy company. Prior to this, Myesha held the same role at Global Blood Therapeutics, Inc., a biotechnology company focused on treatment options for blood-based disorders. Previously, Myesha led the integrated communications function at ZS Pharma, Inc., (acquired by AstraZeneca PLC), and Hyperion Therapeutics, Inc., (acquired by Horizon Pharma). Earlier in her career, Myesha served in various communications roles with increasing responsibility at other publicly traded biotechnology companies. Myesha earned a BA in Business with a concentration in Communications from Holy Names University.